Marcus Schindler, Executive Vice President for Research & Early Development and Chief Scientific Officer (CSO)

Dr Schindler joined Novo Nordisk in January 2018 as Senior Vice President for External Innovation and Strategy.
From March 2018 to 2021 he was Senior Vice President for Global Drug Discovery and in March 2021 Dr Schindler was appointed Executive Vice President Research & Early Development and Chief Scientific Officer.

Prior to joining Novo Nordisk Dr Schindler was Vice President, head of Cardiovascular and Metabolic Diseases innovative Medicines (CVMD iMed) at AstraZeneca, Sweden. From 2009-2012 he was head of Research at (OSI) Prosidion, Oxford, UK. From 2000-2008 he worked in various leadership roles at Boehringer Ingelheim, Germany after having started his career with Glaxo Wellcome/GSK, UK in 1997. Dr Schindler holds a PhD from the University of Cambridge, UK.

Dr Schindler is a Supervisory Board Member of Innate Pharma S.A., France and Adjunct Professor of Pharmacology at the University of Gothenburg, Sweden.

  • 1997 : Doctor of Philosophy (PhD), University of Cambridge, UK
  • 1994 : Diplom-Biologe (MSc), University of Göttingen, Germany

Dr Schindler is a German national, born September 1966.